Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Obesity is a global health burden and an important risk factor for cardiovascular and kidney disease. Obesity-related kidney injury develops through hyperfiltration, oxidative stress, and inflammation. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual GLP-1/GIP agonists induce weight loss and improve renal outcomes in type 2 diabetes; however, their effects in obese individuals without diabetes remain unclear.
Electronic databases were searched through September 2025 for randomized controlled trials enrolling adults with obesity but without diabetes that reported kidney outcomes—estimated glomerular filtration rate (eGFR) or urinary albumin-to-creatinine ratio (UACR). Trials including patients with diabetes were excluded. Network meta-analyses were performed using R 4.4.1 (netmeta 2.3-0, gemtc 1.0-1) under random-effects models. Treatment effects were expressed as mean difference (MD) for eGFR and ratio of means (ROM) for UACR; treatment ranking was assessed using surface under the cumulative ranking curve (SUCRA).
Seven placebo-controlled trials were included (three with semaglutide, two with tirzepatide, and one with retatrutide). A total of 23,885 patients were analyzed. The mean age ranged from 44.9 to 65.3 years, the mean body mass index from 33.3 to 38.3 kg/m², and the mean eGFR was above 80 mL/min/1.73 m² in all studies except the SMART and SUMMIT trials (65 and 55.3, respectively). The mean UACR was below 30 mg/gCr in all trials except SMART (251 mg/gCr). Active agents reduced UACR vs placebo (ROM 0.68–0.88). Semaglutide showed the largest reduction (ROM 0.68 [95% CI 0.45–1.04]; SUCRA 0.76), followed by Retatrutide (0.71).For eGFR, Retatrutide significantly improved eGFR (MD 8.45 mL/min/1.73 m², 95% CrI 3.52–13.38; SUCRA 0.995), with low heterogeneity (τ = 1.35, I² ≈ 21%). Semaglutide (SUCRA 0.36; MD 0.33 [–1.74, 2.12]) and Tirzepatide (0.49; 0.94 [–1.36, 3.85]) showed smaller, nonsignificant effects. Consistent findings across frequentist and Bayesian analyses strengthened result robustness.
Among obese adults without diabetes, Retatrutide produced the largest improvement in eGFR, while Semaglutide and Retatrutide most effectively reduced UACR. Incretin-based therapies may confer renal benefits beyond glycemic control, supporting further evaluation of dual GLP-1/GIP agonists in nondiabetic obesity-related kidney disease.
